- Anixa Biosciences Inc ANIX has announced that a genomic variant analysis indicates that its potential compounds may be more effective against the Delta variant than the original wild-type SARS-CoV-2.
- Anixa's program, in collaboration with European partner MolGenie, focuses on identifying novel, small molecule inhibitors of Mpro, the main protease of the virus.
- The current compounds that Anixa is synthesizing and evaluating have demonstrated their ability to inhibit the function of this protein, which the virus needs to replicate.
- Sequence analysis of several Delta variant samples demonstrates that the Mpro enzyme often has a mutation that replaces an asparagine (an amino acid) with leucine (another amino acid) near the binding site.
- This change makes the binding pocket of Mpro more hydrophobic, thus suggesting Anixa's compounds will be more potent inhibitors of the variant Mpro than the wild-type (original).
- Price Action: ANIX shares are up 9.45% at $4.98 during the market session on the last check Wednesday.
- Photo by Arek Socha from Pixabay
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.